Therapy for disseminated germ cell tumors (GCT) has been successful with 70-80% of patients being cured with front line chemotherapy. However, for those 20-30% of patients with extra-gonadal primaries or refractory disease, the response to therapy is poor with only 3-30% surviving disease-free after second line agents. One approach to treating resistant disease is the development of strategies to augment the chemotherapeutic agents that have been so successful in the majority of GCT patients. Little is known about the role of DNA repair systems in GCT's except that efficient repair appears to make tumor cells resistant to therapy. We have observed that GCT's express high levels of Ape1/ref-1 compared to normal tissues. Ape1/ref-1 is a multifunctional protein with DNA base excision repair (BER) activity and redox activity required for activation of specific transcription factors including Fos, Jun, NFkappaB, HIF-1alpha (hypoxia inducible factor), p53, and PAX5. This novel combination of functions links Ape1/ref-1 with resistance to many of the therapeutic agents (bleomycin, cisplatin, radiation, and VP-16) used to treat GCT's by acting as direct substrates for BER or indirectly by altering signaling through transcription factors regulated by Ape1/ref-l. Based on this information, we hypothesize: High level expression of Ape1/ref-1 in GCT's is a functional marker of disease which 1) is predictive of high risk disease and 2) can be manipulated to gain a therapeutic advantage. The major thrust of this proposal is to characterize the molecular biology of Ape1/ref-1 in GCT's as it relates to the clinical course of patients and the response of GCT cells to therapeutic agents. To approach this goal, we have developed four Specific Aims:
Specific Aim1 : Determine the relative expression of, Ape1/ref-1in good prognosis and high-risk GCT's. This takes advantage of the wealth of clinical GCT material available at Indiana University.
Specific Aim 2 : What is the role of Ape1/ref-1 in GCT progression and development, including cell growth, apoptosis, cell cycle, and differentiation? That is how does the high level expression of Ape1/ref-1, including over-expression of repair, redox, and nuclear localization domain mutants independently affect the ability of GCT cells to grow as cancer cells.
Specific Aim 3 : How do changes in the redox status of Ape1/ref-1 affect repair function? Using site-specific mutants, determine which cysteine residues specifically control repair function of Ape1/ref-l? Specific Aim 4: How do alterations in the repair and redox functioning of Ape1/ref-1 affect the response of GCT cells to therapeutic agents? Using what we learn in Aims 2 & 3, how can we alter the resistance of GCT cells to therapeutic agents. Through these analyses, we hope to determine the underlying mechanisms by which Ape1/ref-1 function is linked to the progression of testicular cancer. If any mutants are shown to sensitize the GCT cell lines to chemo-/IR agents, as expected, this will set the stage for future gene therapy approaches to sensitize GCT's to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA094025-01A2
Application #
6611824
Study Section
Radiation Study Section (RAD)
Program Officer
Okano, Paul
Project Start
2003-08-05
Project End
2008-07-31
Budget Start
2003-08-05
Budget End
2004-07-31
Support Year
1
Fiscal Year
2003
Total Cost
$235,376
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Pediatrics
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Yang, Jie; Kawasaki, Kazuhiko; Lee, Moses et al. (2016) The dentin phosphoprotein repeat region and inherited defects of dentin. Mol Genet Genomic Med 4:28-38
Dulin, David; Vilfan, Igor D; Berghuis, Bojk A et al. (2015) Backtracking behavior in viral RNA-dependent RNA polymerase provides the basis for a second initiation site. Nucleic Acids Res 43:10421-9
Vascotto, Carlo; Bisetto, Elena; Li, Mengxia et al. (2011) Knock-in reconstitution studies reveal an unexpected role of Cys-65 in regulating APE1/Ref-1 subcellular trafficking and function. Mol Biol Cell 22:3887-901
Onyango, David O; Naguleswaran, Arunasalam; Delaplane, Sarah et al. (2011) Base excision repair apurinic/apyrimidinic endonucleases in apicomplexan parasite Toxoplasma gondii. DNA Repair (Amst) 10:466-75
Rohrabaugh, Sara L; Hangoc, Giao; Kelley, Mark R et al. (2011) Mad2 haploinsufficiency protects hematopoietic progenitor cells subjected to cell-cycle stress in vivo and to inhibition of redox function of Ape1/Ref-1 in vitro. Exp Hematol 39:415-23
Jedinak, Andrej; Dudhgaonkar, Shailesh; Kelley, Mark R et al. (2011) Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages. Anticancer Res 31:379-85
Kelley, Mark R; Luo, Meihua; Reed, April et al. (2011) Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. Antioxid Redox Signal 14:1387-401
Luo, Meihua; He, Hongzhen; Kelley, Mark R et al. (2010) Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal 12:1247-69
Zou, Gang-Ming; Lebron, Cynthia; Fu, Yumei (2010) RNAi knockdown of redox signaling protein Ape1 in the differentiation of mouse embryonic stem cells. Methods Mol Biol 650:121-8
Nyland, Rodney L; Luo, Meihua; Kelley, Mark R et al. (2010) Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1). J Med Chem 53:1200-10

Showing the most recent 10 out of 36 publications